Skip to Main Content

You’re reading the web edition of STAT Health Tech, our guide to how tech is transforming the life sciences. Sign up to get this newsletter delivered in your inbox every Tuesday and Thursday. 

‘Move fast and break things’ meets medicine


When the trial of Elizabeth Holmes finally begins next week, it will once again put the Theranos saga in the spotlight. No matter its outcome, Casey reports, there may be fallout for the biotech and digital health sectors, which have raised significant sums in the past year — in some cases, without as much evidence in hand as one might expect. Holmes “was allegedly able to exploit some of the exuberance of the Silicon Valley types for a health care product,” said Harvard’s Glenn Cohen. If she’s acquitted, he added, it could bolster the case for more aggressive marketing and disrupt-speak that outpaces the evidence. Read more in the story.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.